Accelerating Clinical Trials in Rare Disease - Understanding Asia’s success as a rare disease clinical trial location
This webinar looks at Asia’s rare disease clinical trial landscape, why China is an increasingly attractive location for rare disease trials and critical program strategies to consider.
Expedited clinical development strategies for China
A two-part webinar interview and panel discussion with exclusive insights into China’s regulatory environment, the advantages of involving China sites, and strategies to accelerate entry in China.
Asia Pacific: The solution for accelerating your clinical trial program
Presented By Katrina Norial at OCT Southeast. In this presentation Katrina Norial discusses Novotech’s capabilities, ensuring clinical trial continuity during COVID-19 and leveraging regional advantages to accelerate development.
The benefits of running clinical trials in China
During this webinar we will discuss how China offers a significant opportunity for biotech companies to accelerate their clinical development.
Achieving regulatory milestones & meeting commercial goals
Gain exclusive insight into the world of product development planning and regulatory affairs from industry experts to understand the importance of a streamlined and focused global program strategy.
Managing Global Studies with Regional Partners
In this webinar, you'll learn about 1) Working with specialist CRO partners to maintain speed, flexibility, “fit” and regional expertise, 2) Leveraging technology and gold standard systems to provide integrated global management structure and reporting and 3) Advantages and tradeoffs of different global clinical trial setups.
Accelerating Clinical Trials in Australia and Asia – Presented by Steven Roan at OCT USA
Steven Roan breaks down the acceleration of clinical trials in Australia and Asia. The presentation is broken into three main segments. An introduction to Novotech and how Asia-Pacific is handling the COVID-19 pandemic, what Novotech is doing to support companies in these times, and finally talking about the benefits of working in Asia-Pacific for clinical trials.
Running First-in-human and Vaccines Studies in Australia
A US Investigational New Drug (IND) submission is not necessary to initiate first-in-human clinical trials in Australia. FIH trials in Australia are of high quality and are acceptable to other regulatory agencies in support of later Phase clinical trials.
The Australian Solution to expediting your GMO clinical trial
Learn more about expediting your clinical trials in Australia with a focus on GMO products.
Advancing oncology trials in Asia-Pacific
A growing number of biotechnology companies are looking at the Asia-Pacific region to run their clinical trials in oncology. While Australia and New Zealand are preferred locations to run early phase trials, sponsors often look at Asia for large late phase clinical studies.
Asia-Pacific – a Global hub for Hepatology Clinical Trials
Liver diseases are highly prevalent in the Asia-Pacific region. The region hosts some of the most active key opinion leaders and investigators with strong experience working with biotechnology companies on hepatology trials.
Clinical Trial Continuity in Asia-Pacific June 2020
Sites across the Asia-Pacific region have quickly changed how they manage trials, and most are able to deliver the clinical trial services their clients need. Biotech companies are currently initiating more clinical trials in Asia and Australia/New Zealand than in North America.